MoonLake Immunotherapeutics
MLTX
130 hedge funds and large institutions have $2.77B invested in MoonLake Immunotherapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 52 reducing their positions, and 27 closing their positions.
19% more capital invested
Capital invested by funds: $2.34B → $2.77B (+$434M)
5% more call options, than puts
Call options by funds: $39.6M | Put options by funds: $37.7M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
2.06% less ownership
Funds ownership: 94.65% → 92.59% (-2.1%)
4% less funds holding
Funds holding: 136 → 130 (-6)
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
29% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$56.2M |
| 2 |
RI
RTW Investments
New York
|
+$30.2M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$20.7M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$14.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$34.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.3M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$17.2M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$17M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.7M |
MLTX Hedge Fund Activity: Q2 2025 in Review
130 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2025, worth a combined $2.77B — up 19% from $2.34B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MLTX and 23 opened new positions — a net loss of 4 holders — while 52 trimmed existing stakes and 37 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $56.2M. The largest seller was Polar Capital Holdings, cutting an estimated $34.7M.
- 130 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2025, down from 136 in Q1 2025.
- Funds reported $2.77B of MoonLake Immunotherapeutics stock for Q2 2025, up 19% quarter-over-quarter.
- 23 funds opened new MoonLake Immunotherapeutics positions in Q2 2025 and 27 closed out, a net change of -4 holders.
- The largest MoonLake Immunotherapeutics buyer in Q2 2025 was Avoro Capital Advisors, an estimated $56.2M added.
- The largest MoonLake Immunotherapeutics seller in Q2 2025 was Polar Capital Holdings, an estimated $34.7M sold.
Based on aggregated 13F filings for Q2 2025.